“To develop a treatment regimen for severe coronavirus pneumonia ... a model of fatal acute respiratory distress syndrome in animals was created (director - professor V.N. Karkishchenko). After 72 hours of the experiment, all 100% of the animals died from the development of severe interstitial pulmonary edema and alveolitis, ”the agency said.
At the same time, the introduction of Dalargin allowed a 3.9-fold reduction in the release of pro-inflammatory cytokines and significantly increased animal survival.
“From 70 to 100% of animals survived with different drug administration regimens,” they said.
FMBA is already starting clinical trials of Dalargin in severe coronavirus pneumonia accompanied by respiratory failure.
"The highly reliable effect of the drug, which prevents the development of acute respiratory distress syndrome in the experiment and allows animals with interstitial pulmonary edema to survive, gives hope for its effectiveness in the most severe forms of new coronavirus infection in humans," said agency head Veronika Skvortsova.
On March 28, FMBA presented a treatment regimen for coronavirus infection COVID-19 based on the antimalarial drug Mefloquine.
Skvortsova also said that in Russia they created prototypes of devices for artificial ventilation of the lungs, which will allow simultaneous ventilation of the lungs of several patients.